Wearable Injectors and Connected Devices Conference will provide key regulatory updates
SMi Group reports: Gain insights into developments in wearable devices in clinical trials and adapting to decentralised trials during the pandemic.
- (1888PressRelease) July 14, 2021 - Wearable Injectors and Connected Devices Conference will provide key regulatory updates including guidance on MDR requirements and the impact of Brexit on data collection will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.
You can view the two-day agenda and speaker programme on the event website:
www.wearable-injectors.co.uk/1888pr3
A Regulatory Outlook including key sessions on:
Impact of Medical Device Regulation on Drug Device Combination Products
Introduction of MDR requirements
Impact of MDR requirements on Drug Device Combinations
Complexity in regulating connected devices
Julia Frese, Director, Medical & Health Services, TάV SάD
A regulatory outlook for wearable connected devices
The use of digital technologies how are they used in industry and in decision-making
An overview of the current regulatory framework
Currently existing recommendations
Data generation and future considerations
Solange Corriol-Rohou, Senior Director Regulatory Affairs and Policy, Europe, AstraZeneca
MDR Implementation for On-Body Injectors
Integral drug/device combination products and Article 117
Non-integral drug/device combination products and aspects to be considered for import, distribution, authorised representative, re-packaging & re-labelling
Considerations for pharma industry when implementing relevant MDR requirements
How will the MDR impact the future of the drug/device combination products industry
Andreas Brand, Managing Director, Pro3 Management partnering with Congenius
Regulatory Considerations for On-Body Delivery Systems
Regulatory analysis of on-body delivery systems as complex delivery devices
FDA expectations for on-body delivery systems
Regulatory considerations for on-body delivery systems as a combination product
Priti Baker, Manager Regulatory Affairs Combination Products and Devices, Biogen
Registration is live on the website and a saving of £100 is available for bookings made before 31st August 2021. Register online at www.wearable-injectors.co.uk/1888pr3
Proudly sponsored by: Quantex-arc and Avery Dennison Medical
Contact Information:
For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email:
hsidhu ( @ ) smi-online dot co dot uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses, and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam